Durvitan is commonly used for temporary, symptomatic support relevant to symptoms that interfere with daily functioning due to fatigue and lack of rest. It may assist with maintaining a sense of stability in wakefulness and alertness, which may support patients experiencing symptoms that interfere with daily functioning due to occasional tiredness. The medication is indicated for the relief of the occasional and transient sensation of lack of strength or physical weakness.

The medication is applied in addressing symptom clusters that may become temporarily disruptive, specifically transient drowsiness, hypovigilance, and subjective lack of strength. The use is relevant for easing the symptom burden of sleepiness, as it generally supports temporary wakefulness and vigilance.

---

Contexts and Benefits

In relevant clinical contexts, Durvitan is commonly used when short-term symptomatic assistance is needed to help with the occasional symptoms of fatigue. It is applied across domains where additional symptomatic support is needed to assist with maintaining functional stability and supporting focus in situations involving perceived strain or extended mental effort.

Quick Fact: Relief for Transient Drowsiness The prolonged-release format is applied when patients experience symptoms associated with acute or disruptive episodes of tiredness, and contributes to easing the overall symptom burden over an extended period.

Regulatory References

1. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

Eligibility for Durvitan Use: Official Regulatory Status

Eligibility for Durvitan (Caffeine Anhydrous Prolonged-Release) is strictly governed by governmental regulatory documents, which define specific populations that are permitted, restricted, or prohibited from using the medicine.

Absolute Contraindications (Do Not Use)

Durvitan is contraindicated and must not be used by patients with:

• Known hypersensitivity to caffeine, other methylxanthines, or any excipient.
• Severe cardiovascular disorders or uncontrolled hypertension.
• Epilepsy or psychic disorders involving nervous excitement, insomnia, or states of anxiety.
• Gastro-duodenal ulcer or severe hepatic dysfunction.
• Children under 12 years of age.

Conditional Use and Restrictions

Population Group	Regulatory Status
Approved Age Group	Adults and adolescents 12 years of age and older.
Pregnancy	Use requires physician monitoring/consultation; may be dangerous for the fetus.
Lactation (Breastfeeding)	Must be avoided as caffeine passes into breast milk.
Diabetes/Hepatic Insufficiency	Use requires caution due to potential metabolic effects or altered elimination.

Interactions with other medicines and products

Official regulatory information outlines specific restrictions and interactions for the active ingredient, Caffeine.

Classification	Interacting Medicines & Products
High-Risk Combination	Ephedrine and other Sympathomimetic Stimulants
Exposure Modification	Cimetidine, Fluvoxamine, Oral Contraceptive Steroids, Quinolone Antibiotics (e.g., Enoxacin), Mexiletine
Therapeutic Antagonism	Adenosine, Dipyridamole (Cardiac Stress Test Agents)
Altered Clearance	Lithium, Theophylline

---

Interactions primarily occur through additive pharmacodynamic effects or interference with the Cytochrome P450 1A2 (CYP1A2) enzyme, which is responsible for clearing caffeine. Co-administration with CYP1A2 inhibitors (e.g., Fluvoxamine, Cimetidine) significantly inhibits caffeine elimination, leading to increased plasma exposure of the drug. The regulatory profile specifically warns against combining with potent stimulants to prevent excessive effects.

Interaction-Related Constraints

• Timing Requirement: Caffeine must be avoided for a specific period (up to 24 hours, as stipulated by the agent's label) prior to diagnostic procedures using Adenosine or Dipyridamole.
• Substance Limitation: Intake of caffeinated foods, beverages, and other products must be limited to prevent reinforcing the stimulant effects. Alcohol is also officially advised to be avoided.
• Pharmacokinetic Outcome: Caffeine is documented to increase the clearance of Lithium, which can result in decreased Lithium plasma levels.

Modulating Key Receptor-Mediated Signaling

Durvitan acts within domains involving specific receptor- or enzyme-mediated signaling to modify early molecular steps that shape systemic physiological outcomes. By initiating or suppressing specific signaling sequences, this mechanism modulates the signaling output resulting from excessive mediator activity.

---

Regulating Heightened Physiological Pathway Activity

The drug modulates key pathways associated with heightened physiological responses and is relevant in systems where targeted pathway adjustment is required. This activity alters pathway activity toward a diminished excitatory state, which influences the feedback regulation of overactive physiological responses.

---

Influencing Overactive or Dysregulated Cellular Processes

Durvitan engages mechanisms that regulate overactive or dysregulated processes, particularly in biological systems where specific transmitters or mediators dominate the activity. This action drives the homeostatic regulation of processes driven by distinct signaling patterns and results in downstream physiological adjustments.

How to Use Durvitan: Administration Guidelines

Durvitan is a medication intended solely for the oral route of administration. Its usage is governed by specific instructions related to the prolonged-release properties of the hard capsule form, which contains 300 mg of anhydrous caffeine.

Dosing and Frequency

The standard single dose is 300 mg, corresponding to one prolonged-release capsule. The daily intake must be strictly limited, as the maximum recommended dose is 900 mg per day, equivalent to three capsules.

Administration may be given in divided doses throughout the day, but a minimum interval of at least 6 hours must be observed between each 300 mg dose. The medication is intended for temporary and occasional relief; if the intended purpose is not met or symptoms persist after 7 days, use of the product should be re-evaluated.

Preparation and Procedural Constraints

To ensure the controlled, extended-release mechanism functions correctly, the capsule must be swallowed whole and must not be chewed or crushed. The capsule should be ingested with water or some food. A critical procedural constraint is that the last dose of the day must not be taken within the 6 hours immediately preceding bedtime, which is a requirement to manage the stimulant properties.

Population Rules

Use of the product is not recommended for children under 12 years of age. Furthermore, individuals with severe liver alterations are directed to consult a physician prior to using the medicine due to altered metabolic processing.

Research Evidence / Overview of Studies for Durvitan

Evidence for Temporary Relief of Transient Drowsiness and Physical Weakness

Research has studied whether the active compound in Durvitan was studied for temporary feelings of tiredness and subjective lack of strength, which is the primary licensed use. Studies monitored physiological strain and described patterns observed in the study populations for feelings of alertness. Studies reported measurements during the study period for self-reported feelings of wakefulness and subjective discomfort.

Studies on Sustaining Performance Under Fatigue

Studies explored the characteristics of the prolonged-release formula in research contexts involving prolonged periods of wakefulness or sleep deprivation. The compound was studied in short-term trials where participants were kept awake for extended intervals. This research describes how the compound was observed in scenarios designed to examine certain cognitive and motor functions. Data show patterns associated with measured speed in standardized psychomotor vigilance tests.

Study Design: Comparing Against Placebo and Measurement Types

The core evidence is derived from controlled settings using Randomized Controlled Trials (RCTs). These studies randomly assign participants to the active compound or a placebo, allowing researchers to observe patterns. Research examined outcomes using objective measurements, such as those that track reaction time, and subjective measurements, which capture patient-reported outcomes describing perceived discomfort.

Long-Term Data and Follow-Up Duration

Existing studies provide limited insight into the long-term patterns of response for this medicine. Research exploring short-term symptom changes is widely available, and follow-up durations were limited in most key trials to acute periods. Long-term effects are not fully established. The evidence base primarily describes group patterns observed over acute periods.

Evidence in Different Groups of People

The majority of the research has focused on healthy, young to middle-aged adult volunteers, including those placed in research scenarios observing responses during sleep deprivation. However, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes in older adults or individuals with other medical conditions (comorbidities). Research does not determine whether an individual in these less-studied populations will respond similarly.

What the Scientific Literature Indicates is Still Uncertain

The scientific literature highlights several areas where certainty remains low. Findings were mixed in some trials when assessing whether the compound only evaluates outcomes related to caffeine withdrawal or if it produces similar changes in people who do not normally consume caffeine. The results apply only to the specific populations and controlled conditions studied.

Key Studies & References Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) - Durvitan Patient Leaflet (Prospecto 57311)

Common questions about Durvitan (FAQ)

Q: What is the main difference between Durvitan and common over-the-counter vitamins?

According to official product information, Durvitan is classified as a Central Nervous System (CNS) Stimulant, a medicine designed to affect the nervous system and increase wakefulness. This is fundamentally different from common vitamins, which are classified as nutritional supplements intended solely to provide dietary support. Therefore, Durvitan and vitamins belong to distinct pharmacological categories with different purposes.

Q: Is Durvitan a type of stimulant?

Yes, Durvitan is officially classified as a Central Nervous System (CNS) Stimulant. Its active ingredient, anhydrous caffeine, is documented to stimulate the nervous system, which is the mechanism by which it relieves transient drowsiness and enhances alertness.

Q: How quickly should someone expect to notice the effects of Durvitan?

Durvitan is engineered as a prolonged-release hard capsule, a design feature that controls how the medicine is absorbed. This means the active ingredient is released gradually over an extended period. The aim of this prolonged release is to provide sustained action and prevent a rapid spike in alertness followed by a quick drop in effect.

Q: Does Durvitan cause dependency if used for a long time?

The active ingredient in this medicine, caffeine, has been associated with the potential for physical dependence when intake is regular and long-term. If regular use is stopped abruptly, some individuals may experience known withdrawal symptoms such as headache, tiredness, or irritability. For this reason, official use is intended for temporary and occasional relief.

Q: Can Durvitan be taken with caffeine?

Official labeling advises that intake of caffeinated foods, beverages, and other products should be limited while using Durvitan. This is a safety instruction intended to prevent reinforcing the medicine’s stimulant effects and reduce the risk of potential side effects.

Q: Is it safe to drive or operate machinery while taking Durvitan?

The medicine’s safety profile lists side effects such as excitement and restlessness as Very Frequent reactions. Given the potential for these frequent side effects, regulatory information notes that caution may be necessary when performing activities that require alertness, such as driving or operating machinery.

Q: How does Durvitan affect people who already have high blood pressure?

Official regulatory documents state that Durvitan is contraindicated and should not be used by individuals who have uncontrolled hypertension (high blood pressure) or other severe cardiac disorders. The regulatory profile specifically restricts its use in these conditions due to the risk of cardiovascular effects.

Q: Can Durvitan cause stomach upset or nausea?

Yes, regulatory documents list adverse reactions affecting the Gastrointestinal System as Frequent side effects. These common reactions can include symptoms like nausea, vomiting, stomach pain, and diarrhoea.

Q: Is Durvitan chemically similar to any common street drugs?

The active ingredient in Durvitan is officially classified as a methylxanthine derivative, which is a type of purine alkaloid. This is a well-defined and widely studied pharmacological class, and the substance is not classified in the same category as illicit street drugs.

Q: What should a person do if they suspect a serious side effect from Durvitan?

If a serious side effect is suspected, the standard approach involves contacting a healthcare professional or emergency services promptly. Serious reactions are also required to be reported to the relevant health authorities, according to public health guidance.

Q: Can Durvitan affect sleep patterns?

Yes. Insomnia (difficulty sleeping) is classified as a Very Frequent side effect. To mitigate the risk of sleep disturbance, the official label includes a time-related constraint specifying that the last dose must not be taken within six hours of intended bedtime.

Q: What does it mean that Durvitan has 'central nervous system' effects?

The classification as a Central Nervous System (CNS) Stimulant means the medicine acts directly on the brain and spinal cord. This action is what produces effects such as heightened alertness enhancement and increased wakefulness, which are central to its approved use for transient drowsiness.

Q: Why do some people say Durvitan helps with focus?

The medicine’s official purpose is to relieve transient drowsiness, which results in the general benefit of alertness enhancement. Research studies have examined this medicine in scenarios designed to observe effects on certain cognitive functions, including measured reaction time and overall vigilance.

Q: If a person forgets to take a dose of Durvitan, what is generally advised?

Official patient guidance describes the general approach for a missed dose: it is generally taken as soon as remembered. However, if the time is close to the next scheduled dose, the standard approach is to skip the missed dose and resume the normal schedule. Taking double or extra doses is typically discouraged.

Q: Is Durvitan considered a controlled substance?

No. The active ingredient, caffeine, is currently not regulated as a controlled substance under the U.S. Controlled Substances Act (CSA) and is not generally classified as such by major international regulatory bodies.

Q: Is Durvitan linked to any mood changes or irritability?

Yes. Irritability is classified as a Frequent side effect in the product safety profile. The medicine is also officially contraindicated in psychic disorders involving nervous excitement or states of anxiety, as its stimulant action is reported to influence mood.

Q: Is Durvitan used in other countries for different conditions?

While Durvitan is approved for transient drowsiness, its active ingredient, caffeine, is utilized in other product contexts globally. This compound is used in combination with other agents for the symptomatic treatment of conditions such as certain types of pain and is recognized for specialized medical uses.

Q: Is Durvitan an SSRI or a similar antidepressant type of drug?

No. Durvitan is classified as a Central Nervous System (CNS) Stimulant belonging to the methylxanthine derivative class. This pharmacological classification and mechanism of action are distinct from SSRIs (Selective Serotonin Reuptake Inhibitors) and other types of antidepressant medications.

Q: How does the official research evidence for Durvitan compare to what is seen online?

Official research is primarily focused on short-term symptom changes observed in controlled settings over acute periods, often in healthy adult volunteers. Regulatory documents note that the scientific literature provides limited insight into the long-term patterns of response and highlights several areas where certainty remains low.

Q: Are there any restrictions on donating blood while taking Durvitan?

The regulatory label does not specifically address blood donation eligibility. However, the consumption of certain active ingredients, including caffeine, may temporarily affect physiological measures like blood pressure, which are assessed during the donation screening process.

Q: Does Durvitan interact with recreational drugs?

Regulatory documents explicitly warn against combining Durvitan with potent stimulants, such as Ephedrine and other Sympathomimetic Stimulants, due to the risk of additive side effects. Scientific literature further describes a heightened risk of severe acute adverse reactions when the active ingredient is combined with other recreational psychostimulant drugs.

Q: Does taking Durvitan with or without food change its effectiveness?

The official administration guidelines state that the capsule should be ingested with water or some food. Taking the medicine with food is a procedural constraint that is described in the official product information.

How to Store and Dispose of Durvitan

The storage and disposal of Durvitan 300 mg prolonged-release capsules must strictly follow regulatory mandates defined in the official product labeling.

---

Official Storage Requirements

Storage Component	Requirement
Environmental Conditions	No special storage conditions are required in terms of temperature or environment.
Child Safety	Must be kept out of the sight and reach of children.
Stability	Do not use after the expiry date indicated on the carton and blister.

Official Disposal Instructions

Medicines must not be disposed of via wastewater or household waste. To protect the environment and ensure proper handling, ask your pharmacist for guidance on how to dispose of unused or expired Durvitan capsules and containers.